Any drugs or therapeutics with a potential to become real treatment and ultimately improve patient outcomes, are required to go a regulatory approval process. This is a necessary yet a complex system to navigate in Canada. In an interview, Micheal Guirguis, Director, Clinical Pharmacology & Data at API talks about one of the biggest industry challenges of ‘the regulatory and financial gap’ that academic researchers, post-doctoral fellows, and innovators face while developing innovative drugs. API is here to help innovators and researchers understand this process and move their ideas through the steps of the regulatory pathway so that they can bring their solutions to real-world patients in a safe and timely manner.
About Micheal Guirguis
Micheal Guirguis is the Director, Clinical Pharmacology & Data at Applied Pharmaceutical Innovation. With over two decades of experience in pharmacokinetics and Pharmacodynamics for drug discovery and drug development process, Micheal leads the design and preparation of clinical pharmacokinetics, clinical study reports, integrated summary documents, development strategies and study protocols at API. He is passionate about empowering students, recent graduates, and postdoctoral fellows and through his extensive experience in PK/PD, he plays a key role in training them on industry projects through API and helping them begin their careers in the life sciences and pharmaceutical industry.